Stocks · News reference

LUCID CAPITAL MARKETS Initiates Coverage On Eloxx Pharma with Buy Rating, Announces Price Target of $38

Aug 20, 2026, 3:43 PMBenzinga Newsdesk

LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Buy rating and announces Price Target of $38.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 24, 2026, 12:06 PMBenzinga Insights
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Picard Medical (AMEX:PMI) shares moved upwards by 34.6% to $4.32 during Monday's pre-market session. The company's market cap stands at $6.5 million. As per the press release, Q2 earnings came out 3
Read original at benzinga
AEMD CYPH ELOX JUNS KAPA
BenzingaAug 24, 2026, 12:59 PMBenzinga Newsdesk
Guggenheim Reiterates Buy on Eloxx Pharma, Maintains $43 Price Target
Read original at benzinga
ELOX
SEC EDGARAug 11, 2026, 9:19 PMSEC EDGAR
8-K filing — Eloxx Pharmaceuticals, Inc. (ELOX)
Filed: 2026-08-11 AccNo: 0001193125-26-345032 Size: 194 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar
ELOX